Novartis Receives EU Approval for Cosentyx’s (secukinumab) Label Update in Patients with Psoriatic Arthritis (PsA)

Shots:

• The label update includes dosing flexibility of Cosentyx up to 300 mg based on clinical response & SC structural data of 24 wks., showing inhibition in progression of joint damage in PsA
• Cosentyx label update is based on safety and efficacy of 300mg in follow-up titration & results from P-III FUTURE 5 study (N=996) @24 wks. showing results of no radiographic disease progression in 90% of patients
• Cosentyx is novel inhibitor for IL-17A in PsA & AS, prescribed to 160,000 patients WW. The updated label is applicable in EU including all EEA countries

Click here to read full press release/ article | Ref: Novartis | Image: Phys